Novel vaccines for type i allergy

Molecular Vaccines: From Prophylaxis to Therapy - Volume 2

Volumn , Issue , 2014, Pages 489-501

  Scheiblhofer, Sandra ^a   Thalhamer, Josef ^a   Weiss, Richard ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84957615922     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-00978-0_4     Document Type: Chapter

References (67)

1. Locksley, R.M.: Asthma and allergic inflammation. Cell 140, 777-783 (2010). doi: 10.1016/j. cell.2010.03.004
2. Mowen, K.A., Glimcher, L.H.: Signaling pathways in Th2 development. Immunol. Rev. 202, 203-222 (2004). doi: 10.1111/j.0105-2896.2004.00209.x
3. Turner, H., Kinet, J.P.: Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 402, B24-B30 (1999)
4. Gilles, S., et al.: Pollen allergens do not come alone: pollen associated lipid mediators (PALMS) shift the human immune systems towards a T(H)2-dominated response. Allergy Asthma Clin. Immunol. 5, 3 (2009). doi:10.1186/1710-1492-5-3
5. Burton, O.T., Zaccone, P.: The potential role of chitin in allergic reactions. Trends Immunol. 28, 419-422 (2007). doi:10.1016/j.it.2007.08.005
6. Morgenstern, V., et al.: Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. Am. J. Respir. Crit. Care Med. 177, 1331-1337 (2008). doi:10.1164/rccm.200701-0360C
7. Behrendt, H., Becker, W.M.: Localization, release and bioavailability of pollen allergens: the influence of environmental factors. Curr. Opin. Immunol. 13, 709-715 (2001). doi:S0952-7915(01)00283-7 [pii]
8. Gruijthuijsen, Y.K., et al.: Nitration enhances the allergenic potential of proteins. Int. Arch. Allergy Immunol. 141,265-275 (2006). doi:10.1159/000095296
9. Williams, M.A., et al.: Disruption of the transcription factor Nrf2 promotes pro-oxidative dendritic cells that stimulate Th2-like immunoresponsiveness upon activation by ambient particulate matter. J. Immunol. 181, 4545-4559 (2008)
10. Eisenbarth, S.C., et al.: Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J. Exp. Med. 196, 1645-1651 (2002)
11. Herrick, C.A., Bottomly, K.: To respond or not to respond: T cells in allergic asthma. Nat. Rev. Immunol. 3, 405-412 (2003). doi:10.1038/nri1084
12. Poltorak, A., et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998)
13. Shimazu, R., et al.: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189, 1777-1782 (1999)
14. Furmonaviciene, R., et al.: The protease allergen Der p 1 cleaves cell surface DC-SIGN and DC-SIGNR: experimental analysis of in silico substrate identification and implications in allergic responses. Clin. Exp. Allergy 37, 231-242 (2007). doi:10.1111/j. 1365-2222.2007.02651.x
15. Sokol, C.L., Barton, G.M., Farr, A.G., Medzhitov, R.: A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat. Immunol. 9, 310-318 (2008). doi:10.1038/ni1558
16. Comeau, M.R., Ziegler, S.F.: The influence ofTSLP on the allergic response. Mucosal Immunol. 3, 138-147 (2010). doi:10.103 8/mi.2009.134
17. Trompette, A., et al.: Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 457, 585-588 (2009). doi: 10.1038/nature07548
18. van Kooyk, Y.: C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem. Soc. Trans. 36, 1478-1481 (2008). doi:10.1042/BST0361478
19. Royer, PJ., et al.: The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. J. Immunol. 185, 1522-1531 (2010). doi:10.4049/jimmunol. 1000774
20. Kjellman, N.I.: Atopic disease in seven-year-old children. Incidence in relation to family history. Acta Paediatr. Scand. 66, 465-471 (1977)
21. Marenholz, I., et al.: An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J. Allergy Clin. Immunol. 123, 911-916 (2009). doi:10.1016/j. jaci.2009.01.051
22. Senthilselvan, A., et al.: Association of polymorphisms of toll-like receptor 4 with a reduced prevalence of hay fever and atopy. Ann. Allergy Asthma Immunol. 100, 463-468 (2008). doi: 10.1016/S1081-1206(10)60472-3
23. Floistrup, H., et al.: Allergic disease and sensitization in Steiner school children. J. Allergy Clin. Immunol. 117, 59-66 (2006). doi:10.1016/j.jaci.2005.09.039
24. von Mutius, E., Vercelli, D.: Farm living: effects on childhood asthma and allergy. Nat. Rev. Immunol. 10, 861-868 (2010). doi:10.1038/nri2871
25. Ege, M.J., et al.: Prenatal farm exposure is related to the expression of receptors of the innate immunity and to atopic sensitization in school-age children. J. Allergy Clin. Immunol. 117, 817-823 (2006). doi:10.1016/j.jaci.2005.12.1307
26. Riedler, J., et al.: Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 358, 1129-1133 (2001). doi:10.1016/S0140-6736(01)06252-3
27. Ege, M.J., et al.: Not all farming environments protect against the development of asthma and wheeze in children. J. Allergy Clin. Immunol. 119, 1140-1147 (2007). doi:10.1016/j.jaci.2007.01.037
28. van Strien, R.T., et al.: Microbial exposure of rural school children, as assessed by levels of N-acetyl-muramic acid in mattress dust, and its association with respiratory health. J. Allergy Clin. Immunol. 113, 860-867 (2004). doi:10.1016/j. jaci.2004.01.783
29. Vogel, K., et al.: Animal shed Bacillus licheniformis spores possess allergy-protective as well as inflammatory properties. J. Allergy Clin. Immunol. 122, 307-312, 312 e301-e308 (2008). doi:10.1016/j. jaci.2008.05.016
30. Lauener, R.P., et al.: Expression of CD14 and Tolllike receptor 2 in farmers’ and non-farmers’ children. Lancet 360, 465-466 (2002). doi:10.1016/S0140-6736(02)09641-1
31. Pfefferle, P.I., et al.: Cord blood allergen-specific IgE is associated with reduced IFN-gamma production by cord blood cells: the Protection against Allergy-Study in Rural Environments (PASTURE) Study. J. Allergy Clin. Immunol. 122, 711-716 (2008). doi:10.1016/j. jaci.2008.06.035
32. Romagnani, S.: The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 112, 352-363 (2004). doi:10.1111/j. 1365-2567.2004.01925.x
33. Chang, T.W., Wu, P.C., Hsu, C.L., Hung, A.F.: Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv. Immunol. 93, 63-119 (2007). doi:10.1016/S0065-2776(06)93002-8
34. Scheinfeld, N.: Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol. Online J. 11, 2 (2005)
35. Calderon, M., Cardona, V., Demoly, P.: One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy 67, 462-476 (2012). doi: 10.1111/j. 1398-9995.2012.02785.x
36. Cox, L., Calderon, M.A.: Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr. Med. Res. Opin. 26, 2723-2733 (2010). doi:10.1185/03007995.2010.528647
37. Frew, A.J.: Allergen immunotherapy. J. Allergy Clin. Immunol. 125, S306-S313 (2010). doi:10.1016/j. jaci.2009.10.064
38. Canonica, G.W., et al.: Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64(Suppl 91), 1-59 (2009). doi:10.1111/j. 1398-9995.2009.02309.x
39. Frew, A.J.: Sublingual immunotherapy. N. Engl. J. Med. 358, 2259-2264 (2008). doi: 10.1056/NEJMct0708337
40. Razafindratsita, A., et al.: Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J. Allergy Clin. Immunol. 120, 278-285 (2007). doi:10.1016/j. j aci.2007.04.009
41. Ball, T., et al.: Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur. J. Immunol. 29, 2026-2036 (1999). doi: 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2
42. Pauli, G., Malling, H.J.: The current state of recombinant allergens for immunotherapy. Curr. Opin. Allergy Clin. Immunol. 10, 575-581 (2010). doi: 10.1097/ACI.0b013e32833fd6c5
43. Bauer, R., et al.: Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J. Allergy Clin. Immunol. 118, 269-276 (2006). doi:10.1016/j.jaci.2006.03.033
44. Purohit, A., et al.: Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy 38, 1514-1525 (2008). doi:10.1111/j. 1365-2222.2008.03042.x
45. Thalhamer, T., et al.: Designing hypoallergenic deriv atives for allergy treatment by means of in silico mutation and screening. J. Allergy Clin. Immunol. 125, 926-934, e910 (2010). doi:10.1016/j.jaci.2010.01.031
46. Haselden, B.M., Kay, A.B., Larche, M.: Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189, 1885-1894 (1999)
47. Albrecht, M., et al.: Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization. J. Gene Med. 10, 1324-1333 (2008). doi:10.1002/jgm.1256
48. Kumar, M., Behera, A.K., Matsuse, H., Lockey, R.F., Mohapatra, S.S.: A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology 97, 515-521 (1999)
49. Rigaux, P., et al.: Immunomodulatory properties of Lactobacillus plantarum and its use as a recombinant vaccine against mite allergy. Allergy 64, 406-414 (2009). doi: 10.1111/j. 1398-9995.2008.01825.x
50. Schmitz, N., et al.: Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J. Exp. Med. 206, 1941-1955 (2009). doi:10.1084/jem.20090199
51. Weiss, R., et al.: Is genetic vaccination against allergy possible? Int. Arch. Allergy Immunol. 139, 332-345 (2006). doi:10.1159/000091946
52. Roesler, E., et al.: Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J. Allergy Clin. Immunol. 124, 1070-1077, e1071-1011, doi:10.1016/j.jaci.2009.06.036 (2009).
53. Weiss, R., Scheiblhofer, S., Roesler, E., Weinberger, E., Thalhamer, J.: mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev. Vaccines 11, 55-67 (2012). doi10.1586/erv. 11.168:
54. Gabler, M., et al.: Immunization with a low-dose rep-licon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J. Allergy Clin. Immunol. 118, 734-741 (2006). doi:10.1016/j.jaci.2006.04.048. S0091-6749(06)00943-2 [pii]
55. Scheiblhofer, S., et al.: Inhibition of type I allergic responses with nanogram doses of replicon-based DNA vaccines. Allergy 61, 828-835 (2006). doi: 10.1111/j. 1398-9995.2006.01142.x. ALL1142 [pii]
56. Leitner, W.W., Bergmann-Leitner, E.S., Hwang, L.N., Restifo, N.P.: Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 24, 5110-5118 (2006). doi:10.1016/j.vaccine.2006.04.059
57. Eifan, A.O., Shamji, M.H., Durham, S.R.: Long-term clinical and immunological effects of allergen immunotherapy. Curr. Opin. Allergy Clin. Immunol. 11, 586-593 (2011). doi:10.1097/ACI.0b013e32834cb994
58. Bal, S.M., Ding, Z., Jiskoot, W., Bouwstra, J.A.: Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J. Control. Release 148, 266-282 (2010). doi:10.1016/j.jconrel.2010.09.018
59. Gutowska-Owsiak, D., Ogg, G.S.: The epidermis as an adjuvant. J. Invest. Dermatol. 132, 940-948 (2012). doi:10.1038/jid.2011.398
60. Blamoutier, P., Blamoutier, J., Guibert, L.: Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. Presse Med. 67, 2299-2301 (1959)
61. Senti, G., et al.: Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 124, 997-1002 (2009). doi:10.1016/j.jaci.2009.07.019
62. Senti, G., et al.: Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinocon-junctivitis: a double-blind, placebo-controlled dose escalation study. J. Allergy Clin. Immunol. 129, 128-135 (2012). doi:10.1016/j.jaci.2011.08.036
63. Dupont, C., et al.: Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J. Allergy Clin. Immunol. 125, 1165-1167 (2010). doi:10.1016/j. jaci.2010.02.029
64. Weiss, R., et al.: Transcutaneous vaccination via laser microporation. J. Control. Release (2012). doi:10.1016/j.jconrel.2012.06.031
65. Bach, D., et al.: Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice. Allergy (2012). doi: 10.1111/all. 12005
66. Senti, G., et al.: Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J. Allergy Clin. Immunol. 129, 1290-1296 (2012). doi:10.1016/j.jaci.2012.02.026
67. Senti, G., et al.: Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl. Acad. Sci. U. S. A. 105, 17908-17912 (2008). doi:10.1073/pnas.0803725105x